Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2001-2-22
pubmed:abstractText
This manuscript describes two sites in a human IgG1 that, when mutated individually or in combination, result in a dramatic increase in C1q binding and complement-dependent cytotoxicity activity. These two residues, K326 and E333, are located at the extreme ends of the C1q binding epicenter in the C(H)2 domain of a human IgG. A mutation to tryptophan at K326 debilitates Ab-dependent cell-mediated cytotoxicity activity. In addition, substitutions of the residues E333 with serine and of K326 with tryptophan in a human IgG2 confer biological activity in the complement-dependent cytotoxicity assay in which the wild-type IgG2 is inactive. This study reveals that the residues K326 and E333 play a significant role in the control of the biological activity of an IgG molecule and can rescue the activity of an inactive IgG isotype.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
166
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2571-5
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:11160318-Amino Acid Substitution, pubmed-meshheading:11160318-Antibodies, Monoclonal, pubmed-meshheading:11160318-Antibodies, Monoclonal, Murine-Derived, pubmed-meshheading:11160318-Antibody-Dependent Cell Cytotoxicity, pubmed-meshheading:11160318-Antigens, CD20, pubmed-meshheading:11160318-Binding Sites, Antibody, pubmed-meshheading:11160318-Carbohydrates, pubmed-meshheading:11160318-Cell Line, Transformed, pubmed-meshheading:11160318-Complement Activation, pubmed-meshheading:11160318-Complement C1q, pubmed-meshheading:11160318-Glutamic Acid, pubmed-meshheading:11160318-Glycosylation, pubmed-meshheading:11160318-Humans, pubmed-meshheading:11160318-Immunoglobulin G, pubmed-meshheading:11160318-Immunoglobulin Isotypes, pubmed-meshheading:11160318-Lysine, pubmed-meshheading:11160318-Mutagenesis, Site-Directed
pubmed:year
2001
pubmed:articleTitle
Engineered antibodies with increased activity to recruit complement.
pubmed:affiliation
Oncology Department, Aventis-Gencell, Hayward, CA 94545, USA.
pubmed:publicationType
Journal Article